arrow_back Back Filing freshness 10-Q Q3 FY2026 SEC EDGAR

Bioventus Inc.

BVS
$10.67 ▼ -0.74 (-6.53%) at close
Healthcare ·Surgical & Medical Instruments & Apparatus ·USSurgical & Medical Instruments & Apparatus
27 Visible periods
30 Metrics
Peer-ranked Benchmarks
Price Chart
57
Health
Fair
Bearish
auto_awesome

Analytical Summary

Bioventus Inc. faces fundamental challenges with weakness in Debt to Equity. The fundamentals warrant careful consideration of downside risks.

Market Cap $729.6M
Dividend Yield —
Revenue Growth 2.7% ↘
Op. Margin 6.8% ↘
ROIC 2.4% ↘
FCF / Share $0.30 ↗
Trailing P/E 118.6x
Price / Book 3.0x
FCF Yield 2.8%
Debt / Equity 0.88
info Valuation on last close. End-of-day price, Nov 5, 2026.

27-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$142.44M
↑ +2.7% —
Net Income Profit after all expenses
$5.99M
↑ +89.8% —
Operating Margin Operating profit as % of sales
6.8%
↓ -45.5% 55th
FCF / Share Free cash flow per share
$0.30
↑ +6.7% —
Long-Term Debt Long-term obligations
$211.08M
↓ -8.1% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Debt to EquityDebt to Equity is concerning (bottom quartile)

Health Breakdown

Profitability ↑
56
Returns ↑
75
Financial Health ↑
17
Cash Quality ↑
92

bar_chart Data from SEC EDGAR XBRL filings

Synced 5 days ago 7 years · 27 quarters